FTC Challenges More Than 100 Patents as Improperly Listed in the FDA’s Orange Book
Date
Today, the Federal Trade Commission (FTC) challenged more than 100 patents held by manufacturers of brand-name asthma inhalers, epinephrine autoinjectors, and other drug products as improperly or...